Toppmeyer D L, Slapak C A, Croop J, Kufe D W
Division of Cancer Pharmacology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115.
Biochem Pharmacol. 1994 Aug 3;48(3):609-12. doi: 10.1016/0006-2952(94)90292-5.
Dolastatin 10, a cytotoxic pentapeptide isolated from the mollusk Dolabella auricularia, exhibits potent antitumor activity. The present studies demonstrated that sublines of murine PC4 and human U-937 leukemia cells expressing a multidrug resistance (MDR) phenotype are cross-resistant to this agent. We also demonstrated that such resistance was reversed by verapamil. While these findings suggested the involvement of the P-glycoprotein (P-gp) in dolastatin 10 resistance, we performed similar studies in a CHO cell line transfected with the human mdr1 cDNA. Expression of P-gp in the transfected cells was associated with resistance to dolastatin 10 by a verapamil-sensitive mechanism. The demonstration that photoaffinity labeling of P-gp was decreased in the presence of dolastatin 10 further supports the interaction of this cytotoxic peptide with P-gp. Taken together, these findings suggest that resistance to dolastatin 10 is conferred, at least in part, by P-gp and that this cytotoxic peptide is a novel member of the MDR phenotype.
多拉司他汀10是一种从软体动物耳状芋螺中分离出的具有细胞毒性的五肽,具有强大的抗肿瘤活性。目前的研究表明,表达多药耐药(MDR)表型的小鼠PC4和人U - 937白血病细胞亚系对该药物具有交叉耐药性。我们还证明,维拉帕米可逆转这种耐药性。虽然这些发现提示P - 糖蛋白(P - gp)参与了多拉司他汀10耐药,但我们在用人类mdr1 cDNA转染的CHO细胞系中进行了类似研究。转染细胞中P - gp的表达通过维拉帕米敏感机制与对多拉司他汀10的耐药相关。在多拉司他汀10存在的情况下,P - gp的光亲和标记减少,这一证明进一步支持了这种细胞毒性肽与P - gp的相互作用。综上所述,这些发现表明,对多拉司他汀10的耐药至少部分是由P - gp介导的,并且这种细胞毒性肽是MDR表型的一个新成员。